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Abstract
Taiwan CDC investigated four cases of recurrent imported vivax
malaria during 2003–2010. Molecular genotyping results and the
lack of inter-episodes travel history indicated that two of the
patients, who acquired vivax malaria in Indonesia and the Solo-
mon Islands, respectively, suffered relapses after an interval of 3–
4 months, despite completing standard-dose primaquine therapy
(30 mg/day for 14 days) for the first episode. Treatment with a
higher dose of primaquine (60 mg/day for 14 days) prevented fur-
ther relapse in both patients. This finding calls for further moni-
toring of the therapeutic efficacy of primaquine in treating
Plasmodium vivax acquired in southeast Asia and Oceania.
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Imported Plasmodium vivax malaria continues to present diag-
nostic and therapeutic challenges in non-endemic regions
[1–3]. P. vivax forms hypnozoites in the liver and requires
primaquine therapy for radical cure. In recent years, primaq-
uine-tolerant P. vivax strains have emerged in the Western
Pacific, southeast Asia, South America and parts of Africa
[2–4]. Primaquine-tolerant strains can relapse after the use
of primaquine regimens involving a lower dosage or a
shorter duration [3–5]. Currently, a primaquine regimen of
30 mg/day (paediatric dose, 0.5 mg/kg/day) for 14 days is
recommended by the Centers for Disease Control and Pre-
vention (Atlanta, USA) and the World Health Organization
to eliminate the hypnozoites of vivax malaria acquired in
Oceania and southeast Asia [5–7].
Taiwan successfully eliminated endemic malaria in 1965 and
remains free from endemic malaria to date [8]. There are
approximately 20–30 imported malaria cases annually. The
Taiwan Centers for Diseases Control (CDC) (Taipei, Taiwan)
have been notified of several cases of apparently recurring
imported vivax malaria in patients who had received appropri-
ate primaquine therapy. Some of these patients had travelled
again to malaria-endemic areas for business after the appar-
ently successful treatment of the first episode. We conducted
a systematic investigation of all such cases occurring over the
past 7 years, using molecular genotyping methods to assist in
differentiating re-infection from true relapse.
From December 2003 to February 2010, there were a
total of 52 confirmed cases of imported P. vivax malaria
(including seven cases of mixed P. vivax and P. falciparum
infection). The diagnosis of imported vivax malaria was estab-
lished by the patients’ travel history, microscopic examina-
tion and nested polymerase chain reaction (PCR) [9].
We reviewed the 52 cases and identified four patients
with repeated episodes. All of these repeated episodes were
caused by P. vivax alone. Blood samples were taken with each
patient’s consent according to the standard investigation pro-
cedure. All patient samples analysed were made anonymous.
The study procedure was approved by the Taiwan CDC and
the Institutional Review Board of National Taiwan University
Hospital for exemption review.
The clinical and epidemiological information for the four
cases was investigated. We defined low-dose primaquine reg-
imen as 15 mg/day (paediatric dose, 0.25 mg/kg/day) for
14 days, standard-dose primaquine as 30 mg/day (paediatric
dose, 0.5 mg/kg/day) for 14 days, and higher-dose primaquine
as 60 mg/day (paediatric dose, 1 mg/kg/day) for 14 days.
The four patients are summarized in Table 1. The first
episode was treated with standard-dose primaquine in
patients 1, 2 and 3; low-dose primaquine was prescribed for
patient 4. The second episodes occurred after an interval of
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3–16 months. The dosage of primaquine was doubled for the
treatment of the second episode. Patients 1, 2 and 3 toler-
ated the higher-dose primaquine, and all of the patients
remained free from both parasitaemia and further clinical
recurrence with regular follow-up for up to 1 year.
Single nucleotide polymorphism analyses of the P. vivax di-
hydrofolate reductase gene [10,11] and PCR-restriction frag-
ment length polymorphism analyses of the P. vivax merozoite
surface protein 3b gene [12,13] were carried out using the
previously described protocols [10,12]. The results (Table 2)
indicated that the second episodes in patient 2, patient 3 and
patient 4 represented relapses, while the second episode in
patient 1 was possibly a re-infection.
Due to the long time intervals (3–16 months) between
the first and second episodes, chloroquine or artesunate
treatment failure can be excluded in these cases. The lack of
travel history between episodes in patient 2 and patient 3
further supports the conclusion that their second episodes
were relapses rather than re-infections. Notably, patient 2
and patient 3 (malaria acquired in the Solomon Islands and
Indonesia, respectively) adhered to the standard-dose pri-
maquine course and completed the treatment after the first
episode. The body mass indices of the four patients (Table 1)
are also in the normal range [14]. Therefore, the failure of
standard-dose primaquine therapy to prevent relapse is not
a result of underdosing in severely obese patients [15,16].
Relapse of vivax malaria despite completion of the recom-
mended standard-dose primaquine regimen raises the possi-
bility that the in vivo efficacy of primaquine as a treatment
for P. vivax acquired in these regions may have decreased.
Treatment with higher-dose primaquine for the second epi-
sode prevented further relapses in both patients. Higher-
dose primaquine therapy, nonetheless, might increase the
risk of methemoglobinaemia and serious haemolysis in
patients with G6PD deficiency [17]. The experiences of
these two patients highlight the need to continue monitoring
of the therapeutic efficacy of primaquine in the treatment of
P. vivax acquired in southeast Asia and Oceania. It is also cru-
cial for both physicians and public health authorities to regu-
larly follow-up returned travellers who acquired vivax
malaria in these regions, after the completion of treatment.
The primaquine dosage administered for radical cure of the
first episode in patient 4 (acquired in Thailand) was only half of
that currently recommended [5–7]. The experience of patient
4 illustrates the risk of treatment failure associated with the
old low-dose primaquine regimen for vivax malaria acquired in
southeast Asia, including those cases acquired in Thailand.
Some reports found that parasites involved in relapse
often bear a genotype different from those present at pri-
mary infection [18,19]. Thus, we cannot be certain that theT
A
B
L
E
1
.
C
li
n
ic
a
l
a
n
d
e
p
id
e
m
io
lo
g
ic
a
l
d
a
ta
o
f
fo
u
r
a
p
p
a
re
n
tl
y
re
c
u
rr
e
n
t
v
iv
a
x
m
a
la
ri
a
c
a
se
s
P
a
ti
e
n
t
A
g
e
(y
e
a
rs
)/
G
e
n
d
e
r
W
e
ig
h
t
(B
M
I)
In
te
r-
e
p
is
o
d
e
tr
a
v
e
l
h
is
to
ry
A
re
a
a
o
f
a
c
q
u
is
it
io
n
In
te
rv
a
lb
(d
a
y
s)
E
p
is
o
d
e
T
h
e
ra
p
y
1
5
0
/M
al
e
6
7
k
g
(2
3
.2
)
Y
e
s
(8
0
-d
ay
st
ay
in
In
d
o
n
e
si
a)
In
d
o
n
e
si
a
1
4
0
1
.1
1
.2
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
3
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
6
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
2
5
2
/M
al
e
7
2
k
g
(2
3
.5
)
N
o
So
lo
m
o
n
Is
la
n
d
s
1
3
3
2
.1
2
.2
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
3
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
6
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
3
3
8
/M
al
e
8
5
k
g
(2
4
.8
)
N
o
In
d
o
n
e
si
a
1
0
4
3
.1
3
.2
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
3
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
C
h
lo
ro
q
u
in
e
5
0
0
m
g/
d
ay
fo
r
2
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
6
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
4
4
6
/M
al
e
6
0
k
g
(2
0
.8
)
Y
e
s
(6
0
-d
ay
st
ay
in
T
h
ai
la
n
d
)
T
h
ai
la
n
d
4
6
9
4
.1
4
.2
A
rt
e
su
n
at
e
2
.4
m
g/
k
g
IV
q
1
2
h
fo
r
3
d
o
se
s,
fo
llo
w
e
d
b
y
2
.4
m
g/
k
g
IV
q
D
fo
r
3
d
ay
s,
th
e
n
1
0
0
m
g/
d
ay
fo
r
3
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
1
5
m
g/
d
ay
fo
r
1
4
d
ay
sc
A
rt
e
su
n
at
e
2
.7
m
g/
k
g
IV
q
1
2
h
fo
r
3
d
o
se
s,
fo
llo
w
e
d
b
y
2
.7
m
g/
k
g
IV
q
D
fo
r
2
d
ay
s,
th
e
n
2
0
0
m
g/
d
ay
fo
r
3
d
ay
s,
th
e
n
P
ri
m
aq
u
in
e
3
0
m
g/
d
ay
fo
r
1
4
d
ay
sc
B
M
I,
b
o
d
y-
m
as
s
in
d
ex
=
w
e
ig
h
t
(k
g)
/(
h
e
ig
h
t
(m
))
2
.
a A
re
a
w
h
e
re
th
e
p
at
ie
n
t
ac
q
u
ir
e
d
th
e
fi
rs
t
in
fe
ct
io
n
w
it
h
im
p
o
rt
e
d
vi
va
x
m
al
ar
ia
.
b
In
te
rv
al
:
ti
m
e
b
e
tw
e
e
n
th
e
fi
rs
t
e
p
is
o
d
e
an
d
th
e
se
co
n
d
e
p
is
o
d
e
.
c
A
d
m
in
is
tr
at
e
d
u
n
d
e
r
d
ir
e
ct
su
p
e
rv
is
io
n
d
u
ri
n
g
h
o
sp
it
al
iz
at
io
n
(m
e
d
ia
n
d
u
ra
ti
o
n
,
6
d
ay
s)
w
it
h
p
at
ie
n
t
e
d
u
ca
ti
o
n
,
fo
llo
w
e
d
b
y
te
le
p
h
o
n
e
m
o
n
it
o
ri
n
g
af
te
r
d
is
ch
ar
ge
u
n
ti
l
th
e
co
m
p
le
ti
o
n
o
f
tr
e
at
m
e
n
t.
CMI Research Note E233
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E232–E234
second episode in patient 1 was definitely a re-infection. It
could be the relapse of a hypnozoite strain other than that
found in the initial parasitaemia. If this is indeed the case for
Patient 1, then the clinical significance will be the same as
that for patient 2 and patient 3.
In summary, this investigation identified two patients with
imported vivax malaria, acquired in Indonesia and the Solo-
mon Islands, respectively, who had a relapse after an interval
of 3–4 months despite completing standard-dose primaquine
therapy for treatment of the first episode. Treatment with
higher-dose primaquine prevented further relapse. This find-
ing calls for further monitoring of the therapeutic efficacy of
primaquine in treating P. vivax acquired in southeast Asia and
Oceania and for regular follow-up after the completion of
treatment in individuals who acquired vivax malaria when
travelling in these regions.
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TABLE 2. Molecular genotyping analyses
Patient
Inter-episode
travel history Episode
pvdhfr polymorphism
InterpretationaF57I/L S58R T61M S117 T/N
1 Yes 1.1
1.2
L
L
R
S
M
M
T
T
Possible Re-infection
2 No 2.1
2.2
F/L
L
R
R
M/T
T
N/T
T
Relapseb
3 No 3.1
3.2
F
F
R
R
M
M
N
N
Relapsec
4 Yes 4.1
4.2
I
I
R
R
T
T
T
T
Relapsec
aBased on the combination of clinical and epidemiological data, Plasmodium vivax dihydrofolate reductase gene (pvdhfr) SNP analyses, and the P. vivax merozoite surface protein
3b gene (pvmsp3b) PCR-RFLP analyses.
bRelapse from one of the initial clones.
cThe first and second episodes had identical pvmsp3b PCR-RFLP patterns.
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